Development of a Test Cancer BioChip for the Cancer BioChip System

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$269,640.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA141962-01A2
Award Id:
95873
Agency Tracking Number:
CA141962
Solicitation Year:
n/a
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
FALCON GENOMICS, INC., 160 North Craig Street, Suite 222, PITTSBURGH, PA, 15213
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
168092323
Principal Investigator:
RULA ABBUDANTAKI
(412) 802-6237
RABBUD@FALCONGENOMICS.COM
Business Contact:
ANTAKI ABBUD
() -
rabbud@falcongenomics.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Recent genomic breakthroughs have revolutionized our understanding of cancer. It is now possible to envision treatment paradigms that would be individualized, targeted and tailored according to the tumor genetic profile . However, high-throughput functional assays capable of identifying and validating potential cancer drugs, based on abnormal tumor gene expression profiles, in a setting that would directly translate to providing recommendations for patient treatment are n ot readily available. The human tumor stem cell assay (HTSCA), also known as anchorage-independent growth assay, has been considered as the gold standard for chemosensitivity testing of patient tumor cells. In its current format, the HTSCA suffers from m any pitfalls that make it unfit for high-throughput clinical testing. Falcon Genomics, Inc. is developing the Cancer BioChip System (CBCS), a rapid, high-throughput, automated, and quantitative anchorage-independent growth assay for the personalized identi fication and validation of inhibitors of cancer cell growth. We will use silencing RNA (siRNA) or short hairpin RNA (shRNA) to inhibit expression of abnormally expressed tumor genes and test their impact on anchorage-independent tumor growth in a high-thro ughput fashion. In this Phase I application, we will develop a Test Cancer BioChip for optimizing plating, transfection, silencing, and cytostatic efficiencies. Results from these studies will validate the CBCS as a tool for cancer target identification an d validation. Through future clinical trials, we anticipate development of the CBCS into a cancer diagnostic and personalized therapeutic tool. PUBLIC HEALTH RELEVANCE: This Phase-1 grant application is relevant to the mission of the National Instit ute of Health since it will provide for a Cancer BioChip System that will assist in the diagnosis and development of cancer therapies. It will initially offer a novel personalized approach to the evaluation and treatment of breast cancer patients. However, it is not limited to breast cancer since all types of cancers that are capable of growing in an anchorage-independent fashion can be tested on the Cancer BioChip System.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government